Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, Bunce CA, Hay CM, Welsh S, Komaroff W, Hachaambwa L, Tarragona-Fiol T, Sayeed E, Zachariah D, Ackland J, Loughran K, Barin B, Cormier E, Cox JH, Fast P, Excler JL. Keefer MC, et al. Among authors: excler jl. PLoS One. 2012;7(8):e41936. doi: 10.1371/journal.pone.0041936. Epub 2012 Aug 3. PLoS One. 2012. PMID: 22870265 Free PMC article. Clinical Trial.
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, Anklesaria P, Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze-Zander C, Kabamba K, Glaunsinger T, Sahay S, Thakar M, Paranjape R, Gilmour J, Excler JL, Fast P, Heald AE. Mehendale S, et al. Among authors: excler jl. AIDS Res Hum Retroviruses. 2008 Jun;24(6):873-80. doi: 10.1089/aid.2007.0292. AIDS Res Hum Retroviruses. 2008. PMID: 18544020 Clinical Trial.
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast P. Ramanathan VD, et al. Among authors: excler jl. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. doi: 10.1089/aid.2009.0096. AIDS Res Hum Retroviruses. 2009. PMID: 19943789 Clinical Trial.
AIDS vaccines and preexposure prophylaxis: is synergy possible?
Excler JL, Rida W, Priddy F, Gilmour J, McDermott AB, Kamali A, Anzala O, Mutua G, Sanders EJ, Koff W, Berkley S, Fast P. Excler JL, et al. AIDS Res Hum Retroviruses. 2011 Jun;27(6):669-80. doi: 10.1089/AID.2010.0206. Epub 2010 Dec 16. AIDS Res Hum Retroviruses. 2011. PMID: 21043994 Free PMC article. Review.
Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors.
Hara H, Hara H, Hironaka T, Inoue M, Iida A, Shu T, Hasegawa M, Nagai Y, Falsey AR, Kamali A, Anzala O, Sanders EJ, Karita E, Mwananyanda L, Vasan S, Lombardo A, Parks CL, Sayeed E, Krebs M, Cormier E, Ackland J, Price MA, Excler JL. Hara H, et al. Among authors: excler jl. Hum Vaccin. 2011 Jun;7(6):639-45. doi: 10.4161/hv.7.6.15408. Epub 2011 Jun 1. Hum Vaccin. 2011. PMID: 21508675
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.
Schmidt C, Smith C, Barin B, Bakhtyari A, Bart PA, Bekker LG, Chomba E, Clumeck N, Ho D, Hoosen A, Jaoko W, Kaleebu P, Karita E, Keefer MC, van Lunzen J, McMichael A, Mehendale S, Peters B, Ramanathan VD, Robinson A, Rockstroh J, Vardas E, Vets E, Weber J, Graham BS, Than S, Excler JL, Kochhar S, Ho M, Heald A, Fast PE. Schmidt C, et al. Among authors: excler jl. Hum Vaccin Immunother. 2012 May;8(5):630-8. doi: 10.4161/hv.19454. Epub 2012 May 1. Hum Vaccin Immunother. 2012. PMID: 22634443 Clinical Trial.
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.
Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, Sayeed E, Polonis VR, Earl PL, Moss B, Robb ML, Michael NL, Kim JH, Marovich MA. Ratto-Kim S, et al. Among authors: excler jl. PLoS One. 2012;7(9):e45840. doi: 10.1371/journal.pone.0045840. Epub 2012 Sep 26. PLoS One. 2012. PMID: 23049876 Free PMC article.
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
Mehendale S, Thakar M, Sahay S, Kumar M, Shete A, Sathyamurthi P, Verma A, Kurle S, Shrotri A, Gilmour J, Goyal R, Dally L, Sayeed E, Zachariah D, Ackland J, Kochhar S, Cox JH, Excler JL, Kumaraswami V, Paranjape R, Ramanathan VD. Mehendale S, et al. Among authors: excler jl. PLoS One. 2013;8(2):e55831. doi: 10.1371/journal.pone.0055831. Epub 2013 Feb 13. PLoS One. 2013. PMID: 23418465 Free PMC article. Clinical Trial.
Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
Kopycinski J, Hayes P, Ashraf A, Cheeseman H, Lala F, Czyzewska-Khan J, Spentzou A, Gill DK, Keefer MC, Excler JL, Fast P, Cox J, Gilmour J. Kopycinski J, et al. Among authors: excler jl. PLoS One. 2014 Mar 7;9(3):e90378. doi: 10.1371/journal.pone.0090378. eCollection 2014. PLoS One. 2014. PMID: 24609066 Free PMC article. Clinical Trial.
155 results